• NEWS . 10 Aug 2020
  • Impact of ticagrelor on coronary artery function in East Asians

  • In a study, researchers hypothesized that ticagrelor might improve coronary microvascular function, and investigated the antiplatelet effect of low-dose ticagrelor in East Asian patients.

    A total of 61 consecutive patients with non-significant coronary disease were randomized 1:1:1 to receive ticagrelor 90 mg twice daily (BID; n=22), ticagrelor 45 mg BID (n=19) or clopidogrel 75 mg once daily (QD; n=20). They were then divided into two groups (ticagrelor vs clopidogrel) for evaluation of coronary artery function and three groups for evaluation of antiplatelet function. 

    Results showed that no difference was observed between the two groups in terms of endothelial dysfunction measures including coronary flow reserve, changes in levels of asymmetric dimethylarginine and cluster of differentiation 40 ligand. However, P-selectin was lower in the ticagrelor group than the clopidogrel group (median [interquartile range]: 15.0 [12.0–21.0] vs 47.5 [23.0–67.5]; p=0.014). Platelet inhibition was significantly different among the three groups (ticagrelor 90 mg BID vs ticagrelor 45 mg BID vs clopidogrel 75 mg QD: 85.57±47.63 vs 120.33±51.09 vs 256.42±55.10; p<0.001).

    The study concluded that low-dose ticagrelor showed satisfactory antiplatelet effect compared with clopidogrel.

    Reference:
    Choi WG, et al. The effect of antiplatelet drug on coronary endothelial and microvascular function: Comparison with ticagrelor and clopidogrel. Korean J Intern Med 2020. doi: 10.3904/kjim.2019.293. [Epub ahead of print]